Marshall Wace
AZN icon

Marshall Wace’s AstraZeneca AZN Stock Holding History

Marshall Wace’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$7.67K – 2952
2025
Q3 		$7.67K Buy
+50
New +$7.57K ﹤0.01% 2815

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Marshall Wace's AZN Position: Q1 2026 in Review

Marshall Wace increased its AstraZeneca (AZN) stake by 8,919% in Q1 2026, buying an estimated $93.9M and bringing the position to 492,446 shares worth $97.1M. The position accounts for 0.1% of the portfolio, ranked #174.

Marshall Wace first reported a position in AZN in Q1 2014 and has held it in 36 quarters since. The position peaked at $254M in Q4 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Marshall Wace held 492,446 shares of AstraZeneca worth $97.1M as of Q1 2026.
  • Marshall Wace bought 486,986 AstraZeneca shares in Q1 2026, an estimated $93.9M.
  • AstraZeneca made up 0.1% of Marshall Wace's portfolio in Q1 2026, its #174 holding.
  • Marshall Wace first reported a position in AstraZeneca in Q1 2014 and has held it in 36 quarters since.
  • Marshall Wace's AstraZeneca position peaked at $254M in Q4 2024.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.